Other AASLD abstracts I missed for $VRTX's Incivek that could be of interest
"#LB-8. Telaprevir Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Coinfected Patients: 24-Week Treatment Interim Analysis."
"#LB-23. Validation of an HCV NS3/4A Sequencing Assay for Evaluating Resistance to Boceprevir, Telaprevir and Protease Inhibitor Candidates in a Clinical Reference Laboratory Setting."
"#248. Follow-up of SVR Durability and Viral Resistance in Patients with Chronic Hepatitis C Treated with Telaprevir-Based Regimens: Interim Analysis of the EXTEND Study."
"#31. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study."
"#32. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the Phase III REALIZE study."
"#35. Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219)"
"#2117. Importance of newly described rare hepatitis C virus NS3 protease resistance mutations in patients treated with telaprevir or boceprevir."
"#2104. Long-term follow-up analysis of the hepatitis C virus NS3 protease in patients treated with telaprevir or boceprevir – a comparison between clonal and deep sequencing."
"#2088. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain From Wild Type Clone in Vivo."
#2105. Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated with a Telaprevir-Based Regimen Regardless of Liver Fibrosis Stage."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.